TGFBI

Across TCGA pan-cancer cohorts, TGFBI Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TGFBI data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TGFBI Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TGFBI expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and READ are the cancer types where TGFBI Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.264	0.693	.001	36	view →
BLCA	OS	Median	All	0.183	0.720	.015	15	view →
READ	DFS	Median	All	0.111	0.820	<.001	12	view →
UCEC	DFS	Median	All	0.914	0.611	.020	10	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	OS	Median	III,IV	0.320	0.729	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TGFBI–OV (OS)

Open the OV breakdown →